Caxton Associates (New York)’s Corcept Therapeutics CORT Stock Holding History

Caxton Associates (New York)’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$536K	Buy	+10,632	New	+$557K	0.02%	318
2020 Q3	–	Sell	-53,222	Closed	-$895K	–	346
2020 Q2	$895K	Buy	53,222 +30,102	+130%	+$423K	0.08%	75
2020 Q1	$275K	Buy	23,120 +1,447	+7%	+$17.9K	0.05%	277
2019 Q4	$262K	Buy	+21,673	New	+$302K	0.04%	304
2017 Q4	–	Sell	-10,300	Closed	-$199K	–	367
2017 Q3	$199K	Buy	+10,300	New	+$154K	0.01%	472

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Caxton Associates (New York)'s CORT Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Corcept Therapeutics (CORT) in Q4 2024: 10,632 shares worth $536K. The stake represents 0.02% of the portfolio and ranks #318 among its holdings. This is a return to the name: Caxton Associates (New York) previously reported a position in CORT as recently as Q2 2020.

Caxton Associates (New York) first reported a position in CORT in Q3 2017 and has held it in 5 quarters since. The position peaked at $895K in Q2 2020. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

Caxton Associates (New York) held 10,632 shares of Corcept Therapeutics worth $536K as of Q4 2024.
Corcept Therapeutics was a new Caxton Associates (New York) position in Q4 2024.
Corcept Therapeutics made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #318 holding.
Caxton Associates (New York) first reported a position in Corcept Therapeutics in Q3 2017 and has held it in 5 quarters since.
Caxton Associates (New York)'s Corcept Therapeutics position peaked at $895K in Q2 2020.
367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.